Literature DB >> 3760893

Anticysticercous antibodies in serum and cerebrospinal fluid in patients with cerebral cysticercosis.

T Corona, D Pascoe, D González-Barranco, P Abad, L Landa, B Estañol.   

Abstract

Fifty-one cases of cerebral cysticercosis proved by surgery or CT scanning were studied prospectively with the ELISA test in order to detect anticysticercous antibodies in blood and CSF. The ELISA test was also performed for detection of antibodies in 20 control patients who had CSF withdrawn during a myelogram and in 119 serum samples of asymptomatic subjects. We found an overall sensitivity of the ELISA test in the blood of 87% with a specificity of 90%. In the CSF we found a sensitivity of 87% with a specificity of 100%. However, when we compared patients with cerebral cysticercosis of a benign type with patients with cerebral cysticercosis of a malignant type we found a serum sensitivity of 75% for the benign group as compared to 93% of the malignant group. The CSF sensitivity was 80% in the benign group and 93% in the malignant group. This difference was statistically significant.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3760893      PMCID: PMC1029010          DOI: 10.1136/jnnp.49.9.1044

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  19 in total

1.  Comparison of serologic tests for human cysticercosis by indirect hemagglutination, indirect immunofluorescent antibody, and agar gel precipitin tests.

Authors:  A K Rydzewski; E S Chisholm; I G Kagan
Journal:  J Parasitol       Date:  1975-02       Impact factor: 1.276

2.  SILENT CYSTICERCOSIS OF THE BRAIN. AN ANALYSIS OF FIVE CASES WITH SPECIAL REFERENCE TO HISTOPATHOLOGY.

Authors:  A SHOWRAMMA; D B REDDY
Journal:  Indian J Pathol Bacteriol       Date:  1963-07

3.  Cerebral cysticercosis in Mexico.

Authors:  L LOMBARDO; J H MATEOS
Journal:  Neurology       Date:  1961-09       Impact factor: 9.910

4.  Cysticercosis of the nervous system; diagnosis by means of the spinal fluid complement fixation test.

Authors:  D NIETO
Journal:  Neurology       Date:  1956-10       Impact factor: 9.910

5.  Cerebral cysticercosis as a cause of unnatural deaths: case report.

Authors:  C S Bhaskaran
Journal:  Indian J Med Sci       Date:  1973-07

Review 6.  Immunological unresponsivensss in parasitic infections.

Authors:  G M Urquhart
Journal:  J Parasitol       Date:  1970-08       Impact factor: 1.276

7.  [Cerebral cysticercosis as a public health problem. I. Introduction].

Authors:  J Humberto Mateos
Journal:  Gac Med Mex       Date:  1972-03       Impact factor: 0.302

8.  Cysticercosis and epilepsy in Africans: a clinical and serological study.

Authors:  S J Powell; E M Proctor; A J Wilmot; I N MacLeod
Journal:  Ann Trop Med Parasitol       Date:  1966-06

9.  Enzyme-linked immunosorbent assay for the diagnosis of cerebral cysticercosis.

Authors:  I N Mohammad; D C Heiner; B L Miller; M A Goldberg; I G Kagan
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

10.  [Immunoelectrophoresis and double immunodiffusion in the diagnosis of human cerebral cysticercosis].

Authors:  A Flisser; R Tarrab; K Willms; C Larralde
Journal:  Arch Invest Med (Mex)       Date:  1975
View more
  13 in total

Review 1.  Tropical medicine.

Authors:  G C Cook
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

2.  Free-GABA levels in the cerebrospinal fluid of patients suffering from several neurological diseases Its potential use for the diagnosis of diseases which course with inflammation and tissular necrosis.

Authors:  A T Zepeda; F J Ortiz Nesme; J Méndez-Franco; E Otero-Siliceo; M Pérez de la Mora
Journal:  Amino Acids       Date:  1995-09       Impact factor: 3.520

3.  Neurocysticercosis--a review of 231 cases.

Authors:  L Monteiro; T Coelho; A Stocker
Journal:  Infection       Date:  1992 Mar-Apr       Impact factor: 3.553

4.  The relationship of antibody levels to the clinical spectrum of human neurocysticercosis.

Authors:  D Zini; V J Farrell; A A Wadee
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-08       Impact factor: 10.154

5.  Immunoglobulin E and G4 antibodies in cysticercosis.

Authors:  J A Short; D C Heiner; R L Hsiao; F L Andersen
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

Review 6.  Proposed diagnostic criteria for neurocysticercosis.

Authors:  O H Del Brutto; V Rajshekhar; A C White; V C Tsang; T E Nash; O M Takayanagui; P M Schantz; C A Evans; A Flisser; D Correa; D Botero; J C Allan; E Sarti; A E Gonzalez; R H Gilman; H H García
Journal:  Neurology       Date:  2001-07-24       Impact factor: 9.910

7.  Humoral immune response in patients with cerebral parenchymal cysticercosis treated with praziquantel.

Authors:  B Estañol; H Juárez; M del C Irigoyen; D González-Barranco; T Corona
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

8.  Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis.

Authors:  Silvia Rodriguez; Pierre Dorny; Victor C W Tsang; E Javier Pretell; Jef Brandt; Andres G Lescano; Armando E Gonzalez; Robert H Gilman; Hector H Garcia
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226

Review 9.  Human cysticercosis and Indian scenario: a review.

Authors:  Kashi Nath Prasad; Amit Prasad; Avantika Verma; Aloukick Kumar Singh
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

Review 10.  Current consensus guidelines for treatment of neurocysticercosis.

Authors:  Hector H García; Carlton A W Evans; Theodore E Nash; Osvaldo M Takayanagui; A Clinton White; David Botero; Vedantam Rajshekhar; Victor C W Tsang; Peter M Schantz; James C Allan; Ana Flisser; Dolores Correa; Elsa Sarti; Jon S Friedland; S Manuel Martinez; Armando E Gonzalez; Robert H Gilman; Oscar H Del Brutto
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.